Teva shells out $135M to wrap Illinois AG's Medicaid pricing fraud suit

courthouse
Teva agreed to a $135 million settlement with Illinois to resolve allegations of fraudulent pricing. (Pixabay)

Fourteen years after Illlinois' attorney general accused Teva of defrauding Medicaid with inflated pricing, the company has agreed to pay $135 million to wrap up the allegations.

The settlement stems from a 2005 lawsuit Attorney General Lisa Madigan filed against Teva and 46 other pharma companies, alleging the drugmakers fraudulently published inflated average wholesale prices that went into calculating Medicaid reimbursement rates. As a result, taxpayers overpaid for Teva drugs, the suit argued.

A Teva spokesperson declined to comment further on the lawsuit.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Since filing the suit, Madigan has recovered more than $436 million in settlements from various companies, according to her office. Litigation is still moving forward against nine drugmakers.

RELATED: Teva's escaped the generics 'death spiral,' but it can't take all the credit: CEO

The settlement helps Teva put one challenge in the rearview mirror as it heads into 2019 with other overhangs. For one, the company is involved in an industrywide generics price-fixing probe, along with Mylan and other generics players. Other challenges include a massive restructuring at Teva and an overall tough environment in generics pricing.

But this week at the J.P. Morgan Healthcare Conferece in San Francisco, Teva CEO Kåre Schultz said generic pricing challenges have stabilized, and that Teva’s investors can expect predictability moving forward after a few rough years.

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.